Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

被引：5

作者：

Usmani, Saad Z. ^{[1
]}

Dimopoulos, Meletios A. ^{[2
]}

Belch, Andrew ^{[3
]}

White, Darrell ^{[4
]}

Benboubker, Lofti ^{[5
]}

Cook, Gordon ^{[6
,7
]}

Leiba, Merav ^{[8
]}

Morton, James ^{[9
]}

Ho, P. Joy ^{[10
]}

Kim, Kihyun ^{[11
]}

Takezako, Naoki ^{[12
]}

Khokhar, Nushmia Z. ^{[13
]}

Guckert, Mary ^{[13
]}

Wu, Kaida ^{[13
]}

Qin, Xiang ^{[13
]}

Casneuf, Tineke ^{[14
]}

Chiu, Christopher ^{[13
]}

Sasser, A. Kate ^{[13
]}

San-Miguel, Jesus ^{[15
]}

机构：

[1] Levine Canc Inst Carolinas HealthCare Syst, Charlotte, NC USA

[2] Univ Athens, Athens, Greece

[3] Univ Alberta Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada

[4] Dalhousie Univ, QEII Hlth Sci Ctr, Halifax, NS, Canada

[5] Ctr Hosp Regional Univ CHRU, Serv Hematol & Therapie Cellulaire, Hop Bretonneau, Tours, France

[6] Leeds Teaching Hosp NHS Trust, St Jamess Inst Oncol, Leeds, W Yorkshire, England

[7] Univ Leeds, Leeds, W Yorkshire, England

[8] Sheba Med Ctr, Tel Hashomer, Israel

[9] Icon Canc Care, South Brisbane, Qld, Australia

[10] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW, Australia

[11] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, Seoul, South Korea

[12] Natl Hosp Org Disaster Med Ctr Japan, Dept Hematol, Tachikawa, Tokyo, Japan

[13] Janssen Res & Dev, LLC, Spring House, PA USA

[14] Janssen Res & Dev, Beerse, Belgium

[15] Clin Univ Navarra CIMA, IDISNA, Pamplona, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1151.1151

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1151

引用

页数：7

共 50 条

[41] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
Munshi, Nikhil C.
Mitsiades, Constantine
Richardson, Paul G.
Anderson, Kenneth C.
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 374 - 375
[42] Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
Kaufman, Jonathan L.
Usmani, Saad Z.
San-Miguel, Jesus
Bahlis, Nizar
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Krevvata, Maria
Pei, Huiling
Ukropec, Jon
Renaud, Thomas
Trivedi, Sonali
Kobos, Rachel
Dimopoulos, Meletios A.
BLOOD, 2019, 134
[43] Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy
Mateos, Maria-Victoria
Szarejko, Monika
Bila, Jelena
Schjesvold, Fredrik
Spicka, Ivan
Maisnar, Vladimir
Jurczyszyn, Artur
Grudeva-Popova, Zhanet
Hajek, Roman
Usenko, Hanna
Thuresson, Marcus
Norin, Stefan
Jarefors, Sara
Richardson, Paul
Pour, Ludek
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S200 - S201
[44] THE EFFICACY OF COMBINATION THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
Szudy-Szczyrek, Aneta
Legiec, Wojciech
Manko, Joanna
Gmyz, Katarzyna
Szczyrek, Michal
Hus, Marek
HEALTH PROBLEMS OF CIVILIZATION, 2015, 9 (02) : 50 - 54
[45] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) AND DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Pelligra, C.
Guo, S.
Parikh, K.
Zhang, S.
Krotneva, M.
Onyekwere, U.
Clancy, Z.
VALUE IN HEALTH, 2018, 21 : S254 - S254
[46] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
Plesner, Torben
Arkenau, Hendrik-Tobias
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Palumbo, Antonio
Lisby, Steen
Basse, Linda
Wang, Jianping
Sasser, A. Kate
Guckert, Mary E.
Yeh, Howard
Ahmadi, Tahamtan
Lokhorst, Henk M.
Richardson, Paul G.
BLOOD, 2015, 126 (23)
[47] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study
Kim, Do Young
Shin, Ho-Jin
Min, Chang-Ki
Eom, Hyeon-Seok
Jung, Jongheon
Kim, Kihyun
Lee, Jae Hoon
Yoo, Kwai Han
Lee, Ji Yun
Byun, Ja Min
Kim, Sung-Hyun
Lee, Ji Hyun
Cho, Hee Jeong
Lee, Sang Min
Do, Young Rok
Park, Sungwoo
Lee, Junglim
Lee, Seung-Shin
Kang, Hye Jin
Park, Young Hoon
Lim, Sung-Nam
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S189 - S190
[48] Lenalidomide plus dexamethasone demonstrates efficacy in the treatment of relapsed or refractory multiple myeloma
不详
FORMULARY, 2008, 43 (02) : 79 - 80
[49] Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor
Chanan-Khan, Asher A.
Lentzsch, Suzanne
Quach, Hang
Horvath, Noemi
Capra, Marcelo
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Qi, Ming
Deraedt, William
Schecter, Jordan
Amin, Himal
Qin, Xiang
Casneuf, Tineke
Chiu, Christopher
Sasser, A. Kate
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[50] Efficacy of lenalidomide plus dexamethasone in relapsed/refractory multiple myeloma: A systematic review
Tandy, Fenia
Hadisurya, Audrey
Suciningtias, Marlyn
Chrystelle, Celine
Kurniawan, Andree
ANNALS OF ONCOLOGY, 2022, 33 : S489 - S489

← 1 2 3 4 5 →